H. Depenbrock

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft et al. · The Lancet Oncology · 2015 · 475 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin

R. Thödtmann, H. Depenbrock, Herlinde Dumez et al. · Journal of Clinical Oncology · 1999 · 151 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu et al. · The Lancet Oncology · 2015 · 131 citations · Full text

Medicine, Oncology, Pharmacology +13

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

H. Depenbrock, Robert Peter, G T Faircloth et al. · British Journal of Cancer · 1998 · 83 citations · Full text

Medicine, Oncology, Pharmacology +16

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

Stefan Boeck, K. Weigang-Köhler, Martin Fuchs et al. · Annals of Oncology · 2007 · 68 citations · Full text

Medicine, Oncology, Pharmacology +9